Veredus Laboratories

Executive Summary

Veredus Laboratories is a Singapore-based diagnostics and biotechnology firm specializing in in-vitro diagnostic (IVD) kits and point-of-care assays. Founded in 2003, the company leverages PCR, Lab-on-Chip, and OSOM® rapid-test technologies to address infectious diseases, food safety, biosurveillance, and clinical chemistry. With a commercial-stage portfolio and 200-500 employees, Veredus serves both clinical and industrial markets across Southeast Asia and beyond. The company's established product lines include tests for diabetes, coagulation, women's health, and gastrointestinal conditions, positioning it as a versatile player in the diagnostic space. Looking ahead, Veredus is well-positioned to capitalize on growing demand for decentralized testing and biosurveillance. Upcoming catalysts include the launch of new multiplex PCR panels for respiratory and vector-borne diseases, which could expand its infectious disease franchise. Additionally, the company may pursue CE marking or FDA clearance for a novel food safety assay, addressing regulatory tailwinds. A potential strategic partnership with a global distributor could accelerate market penetration in emerging economies. These initiatives, combined with the company's proven technology platform, support a positive outlook.

Upcoming Catalysts (preview)

• Q3 2026Launch of multiplex PCR panels for respiratory and vector-borne diseases70% success
• Q2 2026CE marking or FDA clearance for a novel food safety assay60% success
• Q3 2026Strategic partnership for distribution in Southeast Asia65% success